Table 2.
FDA-approved nanomedicines in routine clinical use for breast cancer treatment.
| Name/Manufacturer | Nanocarrier | Drug/Compound | Approval Date | Indication | References |
|---|---|---|---|---|---|
| Doxil® (Janssen Pharmaceutica) | PEGylated Liposome | Doxorubicin | 1995 | Metastatic | [30], [47], [48] |
| Lipodox® (Sun Pharma Global FZE) | PEGylated Liposome | Doxorubicin | 2013 | Metastatic | [28] |
| Myocet® (Sopherion Therapeutics) | Non-PEGylated Liposome | Doxorubicin | 2000 | Metastatic | [31], [32], [49] |
| Lipusu® (Sike Pharmaceutical Co. Ltd) | Liposome | Paclitaxel | 2006 | Non-metastatic | [33], [50], [51] |
| Abraxane® (Celgene) | Albumin | Paclitaxel | 2005 | Metastatic | [36], [37], [38], [52], [53] |
| Genexol-PM® (Samyang Biopharm) | mPEG-PDLLA | Paclitaxel | 2007 | Non-metastatic | [39], [40], [54], [55] |
| Nanoxel® (Fresenius Kabi India Pvt Ltd.) | NIPAM-VP | Paclitaxel | 2006 | Metastatic | [41], [42], [56] |
| Kadcyla® (Hoffmann-La Roche) | Antibody | Trastuzumab/DM1 | 2013 | Metastatic HER2+ | [44], [45], [46], [57] |
| 2019 | Early HER2+, residual disease |
Poly(ethylene glycol): PEG. Poly(ethylene glycol)-poly(lactide acid): mPEG-PDLLA. N-isopropyl acrylamide: NIPAM. Vinylpyrrolidone: VP. Emtansine: DM